# A Phase II Study of Anlotinib in STS Patients

> **NCT01878448** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 166 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT01878448
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-10
- **Final completion:** 2017-04-30
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878448, "A Phase II Study of Anlotinib in STS Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01878448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*